CA2537899A1 - Tissue-specific targeting of therapeutic and imaging agents to caveolae - Google Patents

Tissue-specific targeting of therapeutic and imaging agents to caveolae Download PDF

Info

Publication number
CA2537899A1
CA2537899A1 CA002537899A CA2537899A CA2537899A1 CA 2537899 A1 CA2537899 A1 CA 2537899A1 CA 002537899 A CA002537899 A CA 002537899A CA 2537899 A CA2537899 A CA 2537899A CA 2537899 A1 CA2537899 A1 CA 2537899A1
Authority
CA
Canada
Prior art keywords
caveolae
agent
component
tissue
luminal surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002537899A
Other languages
English (en)
French (fr)
Inventor
Jan E. Schnitzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Sidney Kimmel Cancer Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2537899A1 publication Critical patent/CA2537899A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002537899A 2003-07-31 2004-07-29 Tissue-specific targeting of therapeutic and imaging agents to caveolae Abandoned CA2537899A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/631,481 2003-07-31
US10/631,481 US20040115128A1 (en) 1995-09-08 2003-07-31 Targeting endothelium for tissue-specific delivery of agents
PCT/US2004/024448 WO2005012489A2 (en) 2003-07-31 2004-07-29 Targeting endothelium for tissue-specific delivery of agents

Publications (1)

Publication Number Publication Date
CA2537899A1 true CA2537899A1 (en) 2005-02-10

Family

ID=34115771

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002537899A Abandoned CA2537899A1 (en) 2003-07-31 2004-07-29 Tissue-specific targeting of therapeutic and imaging agents to caveolae

Country Status (6)

Country Link
US (2) US20040115128A1 (https=)
EP (1) EP1664272A4 (https=)
JP (1) JP2007511463A (https=)
AU (1) AU2004261988B2 (https=)
CA (1) CA2537899A1 (https=)
WO (1) WO2005012489A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139058B2 (ja) 2004-06-02 2013-02-06 シドニー キンメル キャンサー センター 新形成または新生脈管構造の検出、画像化および処置のための血管標的
EP1755686A2 (en) * 2004-06-02 2007-02-28 Sidney Kimmel Cancer Center Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
US7810718B2 (en) * 2005-05-12 2010-10-12 Cubic Corporation Variable thickness data card body
US20070106271A1 (en) 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
US9474712B2 (en) * 2005-11-09 2016-10-25 Gearbox, Llc In situ reaction device
US20070106277A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Remote controller for substance delivery system
US9067047B2 (en) * 2005-11-09 2015-06-30 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
US8936590B2 (en) * 2005-11-09 2015-01-20 The Invention Science Fund I, Llc Acoustically controlled reaction device
US8273071B2 (en) 2006-01-18 2012-09-25 The Invention Science Fund I, Llc Remote controller for substance delivery system
US8083710B2 (en) 2006-03-09 2011-12-27 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US8273075B2 (en) 2005-12-13 2012-09-25 The Invention Science Fund I, Llc Osmotic pump with remotely controlled osmotic flow rate
US8992511B2 (en) 2005-11-09 2015-03-31 The Invention Science Fund I, Llc Acoustically controlled substance delivery device
US20080140057A1 (en) 2006-03-09 2008-06-12 Searete Llc, A Limited Liability Corporation Of State Of The Delaware Injectable controlled release fluid delivery system
EP3019203A4 (en) 2013-07-09 2017-04-26 President and Fellows of Harvard College Endothelial cell genes and uses thereof
WO2015006501A2 (en) * 2013-07-09 2015-01-15 President And Fellows Of Harvard College Microvessel endothelial cell surface markers and uses thereof
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602005A (en) * 1989-03-03 1997-02-11 The University Of Virginia Alumni Patents Foundation Primate intra-acrosomal sperm antigen for use in a contraceptive vaccine
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5281700A (en) * 1992-08-11 1994-01-25 The Regents Of The University Of California Method of recovering endothelial membrane from tissue and applications thereof
US5776770A (en) * 1995-09-08 1998-07-07 Beth Israel Deaconess Medical Center Isolation and uses of caveolae
US20030008819A1 (en) * 1995-09-08 2003-01-09 Schnitzer Jan E. Targeting endothelium for tissue-specific delivery of agents
EP0848614B1 (en) * 1995-09-08 2006-04-26 Beth Israel Deaconess Medical Center Isolation of microdomains of caveolae and gpi-anchored proteins

Also Published As

Publication number Publication date
JP2007511463A (ja) 2007-05-10
WO2005012489A2 (en) 2005-02-10
US20070160531A1 (en) 2007-07-12
EP1664272A2 (en) 2006-06-07
EP1664272A4 (en) 2011-05-25
AU2004261988B2 (en) 2007-10-04
AU2004261988A1 (en) 2005-02-10
US20040115128A1 (en) 2004-06-17
WO2005012489A3 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
US20070160531A1 (en) Targeting endothelium for tissue-specific delivery of agents
JP2008189674A (ja) カベオレおよびｇｐｉアンカー蛋白質のマイクロドメインの単離
Huang et al. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice
Beldman et al. Nanoparticle-aided characterization of arterial endothelial architecture during atherosclerosis progression and metabolic therapy
McIntosh et al. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery
Moghimi et al. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system–the concept of tissue specificity
Schnitzer Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo
JP5249248B2 (ja) 膜組み込みペプチドのためのナノ粒子輸送システム
Yap et al. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases
AU2011338487B2 (en) Dosage and administration for preventing cardiotoxicity in treatment with ErbB2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
Tseng et al. Sterically stabilized anti‐idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B‐cell lymphoma model
Dai et al. Human platelets repurposed as vehicles for in vivo imaging of myeloma xenotransplants
Aliyandi et al. Disentangling biomolecular corona interactions with cell receptors and implications for targeting of nanomedicines
JP2010517576A (ja) 肺癌の腫瘍血管を標的とするペプチドおよびその適用
Tang et al. Overcoming the on‐target toxicity in antibody‐mediated therapies via an indirect active targeting strategy
US20030008819A1 (en) Targeting endothelium for tissue-specific delivery of agents
US5914127A (en) Isolation and uses of caveolae
Baumgärtner et al. Phosphatidylethanolamine critically supports internalization of cell-penetrating protein C inhibitor
US20020095025A1 (en) Isolation and uses of caveolae
Massey et al. Caveolae and cancer
US6379647B2 (en) Use of mononuclear phagocytes in in vivo imaging of hypoxic/ischaemic tissue
Fuchigami et al. Characterization of antibody clones that bind exclusively to insoluble fibrin
Simionescu et al. Endothelial specific binding sites for permeant plasma macromolecules: albumin binding proteins
Bennett Biochemical Changes in Human Erythrocyte Membranes during Prolonged Cold Storage Under Blood Bank Conditions
Patierno Role of Chemical Delivery Modes in Toxicological Studies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150310